News
-
-
PRESS RELEASE
Sonnet BioTherapeutics Announces Early Safety Data from the Company’s Phase 1b/2a Clinical Trial of SON-080 in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Met the Study’s Initial Pre-Specified Objective
Sonnet BioTherapeutics successfully completes Phase 1b trial of SON-080 with positive safety profile, paving the way for Phase 2 trial in Diabetic Peripheral Neuropathy (DPN) after potential partnership -
-
PRESS RELEASE
Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers
Sonnet BioTherapeutics Holdings, Inc. announced the publication of clinical data on SON-1010, a tumor-targeted immunotherapeutic drug combining FHAB construct with IL-12 in Frontiers in Immunology, showing favorable safety and tolerability -
PRESS RELEASE
Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update
Sonnet BioTherapeutics Holdings, Inc. successfully raised $4.55 million, published preclinical data on SON-1210, executed NJ NOLs agreement, Phase 1b SON-080 trial enrollment completed, financial results announced for quarter ended Dec 31, 2023 -
-
-
-
-
![Accesswire](/assets/images/accesswire-inline.png)
-
Terrance McCray Joins the Crestcom Network
-
Leveraging Twitter With Generative AI: Enhancing US Equity Investments
-
Sentinel Net Lease Completes Sale of the United HealthCare Customer Service Center in San Antonio, Texas
-
Silence the Woof, Not the Love: Pets IQ Launches World's First AI Recognition Anti-Bark Collar
-
Software Leader Axiros North America, Inc. Selected by CT Communications for Advanced Device Management and Regulatory Testing Services
![EQS Group](/assets/images/eqs-group.png)
-
EQS-Adhoc: Flughafen Wien AG: Julian Jäger and Günther Ofner Reappointed to the Management Board of Flughafen Wien AG for a New Term of Office
-
COFICERT: COFICERT and Hédon Associés sign a strategic partnership for the deployment of the certification standard: ESG 1000
-
Form 8.3 - Lupus alpha Asset Management AG: Crest Nicholson Holdings Plc
-
Blue Cap AG: Annual General Meeting approves dividend of EUR 0.65 per share and appoints two new Supervisory Board members
-
EQS-Adhoc: Nakiki SE: Preliminary results for 2022 and 2023
![Les Echos](/assets/images/les-echos.png)
-
GUILLEMOT CORPORATION: Weekly report share buyback from June 17th 2024 to June 21st 2024
-
Statement of transactions in own shares from June 17, 2024 to June 19, 2024
-
Safran: exclusive discussions to acquire Preligens
-
PR – ICADE – Alexis de Nervaux is named Head of IT and Digital Transformation and joins Icade’s Executive Committee
-
Annual Results for 2023/2024